Johnson & Johnson disclosed that its IL‑23 inhibitor TREMFYA (guselkumab) achieved sustained clinical and endoscopic remission in the QUASAR long‑term extension study, with 80.8% of patients in clinical remission and 53.6% in endoscopic remission at week 140. The study also reported that 78.6% of participants experienced histo‑endoscopic mucosal improvement and that 89% of eligible patients completed treatment through week 140.
The 140‑week data demonstrate that TREMFYA’s benefit is durable over more than three years, a critical attribute for a chronic condition such as ulcerative colitis. No new safety concerns emerged during the extension, reinforcing the drug’s tolerability profile and supporting its continued use in patients who have previously received biologics or JAK inhibitors.
These results strengthen TREMFYA’s position within Johnson & Johnson’s growing immunology portfolio and may broaden its market share in the ulcerative colitis segment. The data also provide a competitive advantage over other biologics and small‑molecule therapies that have not yet demonstrated comparable long‑term durability. The company’s recent FDA approvals for ulcerative colitis (SC induction, September 2025) and Crohn’s disease (March 2025) further expand the drug’s therapeutic reach.
The findings were presented at the European Crohn’s and Colitis Organisation conference in Stockholm, which ran from February 18‑21 2026. The conference is a key forum for new IBD data, and the presentation of these long‑term results underscores TREMFYA’s potential to become a cornerstone therapy for moderately to severely active ulcerative colitis.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.